FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. The method for creating recombinant strain of Enterococcus L3-SARS based on biologically active strain of E. faecium L3 is described, differing in that electroporation of culture of enterococci Enterococcus faecium L3 is carried out with recombinant plasmid DNA pentF-sarsS having SEQ ID No: 1, and a clone of Enterococcus L3- SARS expressing a protein having the amino acid sequence of SEQ ID No: 2. Presented is a recombinant pentF-sarsS plasmid having the nucleotide sequence of SEQ ID No: 1, designed to obtain a clone of Enterococcus L3-SARS expressing a protein having the amino acid sequence of SEQ ID No: 2.
EFFECT: invention solves the problem of expanding the arsenal of technical means for creating vaccines.
2 cl, 4 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT DNA ENSURING PRODUCTION OF THE RECOMBINANT PROTEIN COV1 EXHIBITING IMMUNOGENIC PROPERTIES AGAINST SARS-COV-2 VIRUS | 2021 |
|
RU2776484C1 |
| METHOD FOR CREATING RECOMBINANT ENTEROCOCCUS L3-SARSN1 STRAIN BASED ON BIOLOGICALLY ACTIVE ENTEROCOCCUS FAECIUM L3 STRAIN | 2022 |
|
RU2820058C1 |
| METHOD OF CREATING A LIVE VACCINE AGAINST COVID-19 BASED ON THE PROBIOTIC STRAIN ENTEROCOCCUS FAECIUM L3 AND A LIVE VACCINE ENTEROCOCCUS FAECIUM L3-PENTF-COVID-19 | 2020 |
|
RU2745626C1 |
| RECOMBINANT VACCINE STRAIN FOR LIVE INTRANASAL VACCINE PROVIDING COMBINED PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS | 2022 |
|
RU2782531C1 |
| ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
| ADVANCED CORONAVIRUS VACCINE | 2022 |
|
RU2816182C2 |
| VACCINE FOR THE PREVENTION OR TREATMENT OF CORONAVIRUS INFECTION BASED ON A GENETIC CONSTRUCT | 2020 |
|
RU2747762C1 |
